ArticleAmerican journal of blood research2021

Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country.

Sumeet Mirgh et al.PubMed ↗Full text ↗

No numbers read from the abstract.